These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36512628)

  • 1. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
    Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
    Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
    Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
    Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
    Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
    Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
    Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
    Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
    J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
    Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK
    Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
    Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
    Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
    J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
    Momcilovic M; McMickle R; Abt E; Seki A; Simko SA; Magyar C; Stout DB; Fishbein MC; Walser TC; Dubinett SM; Shackelford DB
    Cancer Res; 2015 Nov; 75(22):4910-22. PubMed ID: 26574479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 15. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.
    Fernández-García F; Fernández-Rodríguez A; Fustero-Torre C; Piñeiro-Yáñez E; Wang H; Lechuga CG; Callejas S; Álvarez R; López-García A; Esteban-Burgos L; Salmón M; San Román M; Guerra C; Ambrogio C; Drosten M; Santamaría D; Al-Shahrour F; Dopazo A; Barbacid M; Musteanu M
    Proc Natl Acad Sci U S A; 2024 Sep; 121(36):e2402913121. PubMed ID: 39186651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
    Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
    Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.